Treatment with trastuzumab demonstrated significant survival benefits for patients with HER2-positive metastatic breast cancers.(7) Furthermore, dual blockade of HER2 with the combination of pertuzumab and trastuzumab, as well as chemotherapy, led to significant improvements in overall survival compared with trastuzumab plus chemotherapy.(8). The gene discussed is ERBB2; the disease is breast carcinoma.